- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery | 388 | PR Newswire | INGLEWOOD, Calif., Jan. 22, 2025 /PRNewswire/ -- ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, proprietary... ► Artikel lesen | |
| TELIX PHARMACEUTICALS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| Fr | AKTIONÄR-Tipp Telix Pharma: Zulassung - darum profitiert auch Eckert & Ziegler | 774 | Der Aktionär | In den USA wird das radiopharmazeutische Diagnostik-Produkt Illuccix bereits regelrecht aus den Regalen gerissen. Entwickler Telix Pharma kann den Top-Seller nun auch in Europa auf den Markt bringen.... ► Artikel lesen | |
| Fr | Why Insignia, Lovisa, Megaport, and Telix shares are charging higher today | 8 | The Motley Fool Australia | ||
| Fr | Scott Power: Telix achieves sustained growth; Pro Medicus wins another contract | 10 | Stockhead | ||
| 16.01. | Telix Pharmaceuticals Limited: Illuccix Receives European Approval | 342 | PR Newswire | MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive... ► Artikel lesen | |
| 16.01. | JP Morgan 2025: Radiopharmaceuticals M&A fuels Telix's busy year | 15 | Pharmaceutical Technology | ||
| 16.01. | Telix Buying Therapeutic Assets From ImaginAb For $45 Million | 12 | pulse2.com | ||
| 15.01. | TELIX PHARMACEUTICALS LIMITED: Illuccix Receives European Approval | - | ASX | ||
| 14.01. | Why CAR Group, Peninsula Energy, Star, and Telix shares are charging higher today | 22 | The Motley Fool Australia | ||
| 13.01. | Telix to Acquire Pipeline, Technology Platform & Facility from ImaginAb | 11 | Contract Pharma | ||
| 13.01. | Telix continues shopping spree with $45M purchase of ImaginAb's preclinical drugs, facility | 6 | FierceBiotech | ||
| 13.01. | Telix Pharmaceuticals Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 13.01. | Telix exceeds FY24 guidance with $142M Q4 revenue | 8 | Seeking Alpha | ||
| 13.01. | AKTIONÄR-Tipp Telix Pharma: Prognose übertroffen - und es geht weiter | 404 | Der Aktionär | Am heutigen Montag startet die diesjährige vielbeachtete JPMorgan Healthcare Conference in San Francisco. Die Bühne wird auch der australische Radiopharma-Spezialist Telix Pharma nutzen, um über die... ► Artikel lesen | |
| 13.01. | TELIX PHARMACEUTICALS LIMITED: Telix JP Morgan Healthcare Conference 2025 Presentation | 9 | ASX | ||
| 13.01. | TELIX PHARMACEUTICALS LIMITED: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue | 8 | ASX | ||
| 13.01. | Health Check: Telix to acquire next-gen therapeutics and biologics platform | 8 | Stockhead | ||
| 13.01. | Telix Pharmaceuticals Limited: Scintimun Commercialization Partnership with Curium Pharma | 286 | PR Newswire | MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an... ► Artikel lesen | |
| 13.01. | Telix takes on 'next-gen' cancer drug candidates through $372m asset buy | 12 | The Market Herald Australia | ||
| 12.01. | Telix Pharmaceuticals Limited: Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform | 442 | PR Newswire | MELBOURNE, Australia and INDIANAPOLIS, Jan. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
165 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 50,48 | 0,00 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,490 | 0,00 % | Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday | ||
| SUMMIT THERAPEUTICS | 23,500 | 0,00 % | Why Summit Therapeutics Stock Is Jumping Today | ||
| SANA BIOTECHNOLOGY | 3,500 | 0,00 % | Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5% - Here's Why | ||
| ABSCI | 4,025 | 0,00 % | Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside | ||
| METAGENOMI | 3,020 | 0,00 % | Metagenomi, Inc.: Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones | MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,530 | 0,00 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| JANUX THERAPEUTICS | 40,250 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 30,020 | -2,66 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| QUANTUM-SI | 2,380 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| ARCELLX | 65,87 | -1,05 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| NUVALENT | 81,33 | 0,00 % | Nuvalent-CEO Porter James Richard verkauft Aktien im Wert von 2,05 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 35,025 | 0,00 % | Rappta Therapeutics enters into a global license agreement with SpringWorks Therapeutics for a pre-clinical first-in-class molecular glue targeting PP2A | Goal to accelerate development and commercialization of the lead asset RPT04402 for the treatment of a subset of uterine cancersFinancials include a $13 million upfront payment and potential... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,110 | 0,00 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen | |
| QIAGEN | 45,520 | -1,12 % | Qiagen zahlt Ende Januar 1,26 US-Dollar je Aktie aus | VENLO (dpa-AFX) - Der Diagnostikspezialist und Labordienstleister Qiagen hat Details zu seinem sogenannten synthetischen Aktienrückkauf in Höhe von rund 300 Millionen US-Dollar bekanntgegeben. Je 36... ► Artikel lesen |
Das Unternehmen TELIX PHARMACEUTICALS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 16,100 Euro und damit +0,62 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELIX PHARMACEUTICALS LIMITED ADR finden Sie auf Wallstreet Online.
